<DOC>
	<DOC>NCT00367640</DOC>
	<brief_summary>To evaluate the safety and efficacy of SLIT compared with placebo for reduction of symptoms and rescue medication usage</brief_summary>
	<brief_title>Safety and Efficacy of Sublingual Immunotherapy (SLIT) Tablets in Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Written consent Grasspollen related allergic rhinoconjunctivitis for at least the last 2 pollen seasons. Sensitised to grass pollen (positive SPT and RAST level of at least class 2). Total symptom score of the RRTSS during the previous pollen season greater than or equal to 12. Safety laboratory resuts within the references ranges Pregnancy, breastfeeding/lactation Had received desensitisation treatment for grass pollen Treatment by immunotherapy with another allergen within the previous 5 years Usual contraindications of immunotherapy such as serious immunopathologic conditions or malignancies Treated with betablockers or under continuous corticotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>